Fundz

Who to call at Debiopharm, and when

Fundz watches for the moments Debiopharm starts buying, and tells you who to reach.

  • An alert the day Debiopharm raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Debiopharm, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Debiopharm. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Debiopharm Partners with Genialis to Utilize AI Software for Biomarker Discovery.

Jan 11, 2026

Contract Type

agreement

LausanneBiotechnologyHealth CareTherapeutics

Description

Debiopharm has deployed Genialis Expressions software to enhance biomarker discovery and analytics. This agreement extends their multi-year collaboration, granting Debiopharm access to Genialis’ technology for better processing of omics data.

Quick answer

Debiopharm Partners with Genialis to Utilize AI Software for Biomarker Discovery. (January 11, 2026). Debiopharm is based in Lausanne, Vaud, Switzerland.

What agreement did Debiopharm announce on January 11, 2026?
Debiopharm has deployed Genialis Expressions software to enhance biomarker discovery and analytics. This agreement extends their multi-year collaboration, granting Debiopharm access to Genialis’ technology for better processing of omics data.
What does Debiopharm do?
Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases.
Where is Debiopharm based?
Debiopharm is based in Lausanne, Vaud, Switzerland.

Source: Fundz verified event record.

Company Information

Company

Debiopharm

Location

Lausanne, Vaud, Switzerland

About

Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. Debiopharm is focused on developing innovative therapeutic agents to outsmart hard-to-treat cancers and has a portfolio of carefully selected targets with first-in-class or best-in-class potential.

Related People

Angela
Likely contact at this company
••••••••@••••••••

See Angela's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Debiopharm's next move

Learn about Strategic plan

Debiopharm signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.